2nd Quarter - Report

FABIANI & COMPANY for EDISON PHARMACEUTICALS

Period 2nd Quarter 2011 Filed Jul 21, 2011 Signed by Gary Martin, CFO

Official filing
Firm
FABIANI & COMPANY
Client
EDISON PHARMACEUTICALS
Income
—
Expenses
—

No amount is shown when the filer reports less than $5,000 for the period, which the form does not ask them to state.

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Defense DEF

Defense Appropriations Act, developmental funding for therapeutics for hereditary and acquired mitochondrial diseases.

LobbyistCovered position, as disclosed
ELIZABETH BARROWS —

Contacted: Defense, Dept of (DOD); SENATE; HOUSE OF REPRESENTATIVES; Defense Advanced Research Projects Agency (DARPA)

Health Issues HCR

Defense Appropriations Act, developmental funding for therapeutics for hereditary and acquired mitochondrial diseases.

LobbyistCovered position, as disclosed
ELIZABETH BARROWS —

Contacted: Defense, Dept of (DOD); Defense Advanced Research Projects Agency (DARPA); SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.